Mortality rates in the BSPAR Etanercept Cohort Study
| Total JIA Cohort | Systemic JIA | Non-systemic JIA | |
|---|---|---|---|
| Subjects (n) | 693 | 99 | 594 |
| Time since registration (person-years) | 4475 | 795 | 3680 |
| Male | 1500 | 329 | 1171 |
| Female | 2975 | 466 | 2509 |
| Total deaths, n (%) | 7 (1%) | 4 (4%) | 3 (0.5%) |
| Male | 1 (0.1%) | 0 | 1 (0.2%) |
| Female | 6 (0.9%) | 4 (4%) | 2 (0.3%) |
| Expected deaths, n | 0.96 | 0.18 | 0.78 |
| Male | 0.46 | 0.10 | 0.35 |
| Female | 0.50 | 0.08 | 0.42 |
| Mortality incidence rate/1,000 person-years (95% CI) | 1.6 (0.6, 3.2) | 5.0 (1.4, 12.9) | 0.8 (0.2, 2.4) |
| Male | 0.7 (0.02, 3.7) | – | 0.9 (0.02, 4.8) |
| Female | 2.0 (0.7, 4.4) | 8.6 (2.3, 22.0) | 0.8 (0.1, 2.9) |
| SMR (95% CI) | 7.3 (2.9, 15.0) | 21.7 (5.9, 55.4) | 3.9 (0.8, 11.3) |
| Male | 2.2 (0.06, 12.2) | – | 2.8 (0.07, 15.8) |
| Female | 11.9 (4.4, 25.9) | 49.5 (13.5, 126.8) | 4.7 (0.6, 17.0) |